These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Nov 7, 2013Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 TrialSUBJECTS TREATED WITH THE INITIAL THREE INJECTIONS OF HERPV SHOWED A STATISTICALLY SIGNIFICANT REDUCTION IN VIRAL SHEDDING, THE PRIMARY ENDPOINT
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced statistically significant top-line results from its Phase 2 randomized,...
Oct 24, 2013Agenus to host conference call beginning at 11 a.m. ET today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its...
Oct 16, 2013Agenus to Report Third Quarter 2013 Financial Results on October 24, 2013; Conference Call to Follow
Agenus Inc. (NASDAQ: AGEN) will release its third quarter 2013 financial results before the market opens on October 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern...
Oct 7, 2013GSK’s Vaccine Candidate Containing Agenus’ QS-21 Stimulon® Reduces Malaria Infection in Phase 3 Trials of Over 15,000 ChildrenSignificant protection shown 18 months post vaccination
Agenus Inc. (Nasdaq: AGEN) today announced that new Phase 3 data for GlaxoSmithKline’s (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus’ QS-21 Stimulon®1 adjuvant, were...
Sep 26, 2013Agenus and Vaxlogic, LLC Execute QS-21 Stimulon® Adjuvant Licensing Agreement for Addiction, Allergy and Respiratory Vaccines
Agenus Inc. (Nasdaq: AGEN) today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon®1...